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There  is increasing  concern  about  the  reliability  of  biomedical  research,  with  recent  articles  suggesting
that  up  to  85% of  research  funding  is wasted.  This  article  argues  that  an  important  reason  for  this  is  the
inappropriate  use  of molecular  techniques,  particularly  in  the  ﬁeld  of  RNA biomarkers,  coupled  with  a
tendency  to exaggerate  the  importance  of  research  ﬁndings.
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. Time to listen!
Most researchers are aware that the translation into clinical
ractice of even the most promising ﬁndings of basic research is
low and rare [1] and that the clinical effectiveness of drugs can-
ot be predicted reliably from early research-based evidence [2].
is ill conceived, poorly executed, inappropriately analysed, inad-
equately reported, side-tracked by bias and stiﬂed by red tape.
The ﬁrst article considers research priorities and questions
their relevance for human health in the context of a worldwide
investment in biomedical research of around US$240 billion [3].
The second highlights the usual absence of detailed written pro- string of ﬁve articles and an editorial printed in the Lancet in
arly 2014 addressed this issue, reaching the staggering conclu-
ion that 85% of biomedical funding is wasted on research that
∗ Tel.: +44 08451964845.
E-mail address: Stephen.bustin@anglia.ac.uk
ttp://dx.doi.org/10.1016/j.bdq.2015.01.002
214-7535/© 2015 The Authors. Published by Elsevier GmbH. This is an open acces
y-nc-nd/4.0/).tocols for and poor documentation of research and comments
on the systematic preference for quantity rather than quality,
and novelty rather than reliability [4]. The third article discusses
the modern approach to the regulation, governance, and man-
agement of biomedical research and emphasises how inefﬁcient
management can easily compromise the interests of patients and
public [5]. The fourth points out that a large percentage of health
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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esearch-associated protocols, full study reports and participant-
evel datasets are rarely available, that there is selective reporting
f methods and results and that this leads to the introduction of
ias, detrimentally effects the care of patients and wastes huge
mounts of research funding [6]. The ﬁnal article re-emphasises
he absolute requirement for accurate, exhaustive and transparent
eporting and notes that whilst reporting guidelines are impor-
ant, they are all much less adopted and adhered to than they
hould be [7]. Finally, the editorial discusses the consistent and
olossal failure of initially promising research ﬁndings to translate
nto improvements in health in light of the many, economic, polit-
cal, social and cultural factors that inﬂuence researchers, funders,
egulators, institutions and companies [8]. The authors make the
evolutionary suggestion that rather than using journal impact fac-
ors to assess academics, it might be more constructive to gauge the
ethodological rigour, transparency of reporting and reproducibil-
ty of results of their output, which would of course facilitate the
ublication of more reliable and biologically relevant data.
. Time to act!
Clarion calls don’t come much louder, insistent or with more
uthority. The authors’ principal recommendations involve pro-
osals to improve every aspect of research project procedures
elating to standardisation, governance and the research environ-
ent infrastructure:
Enhance translational research outcomes by increasing clarity
from researchers, funders and regulators with regards to research
proposal justiﬁcation and transparency of protocols [3].
Make research results more reliable and relevant by ensuring
public availability of protocols, analysis plans, raw data and
providing continuous training and professional development
coupled to reward incentives [4].
Streamline management of biomedical research to make it ﬁt
for purpose by harmonising regulations and processes affecting
research, together with appropriate research designs and moni-
toring [5].
Make information more widely available by adopting per-
formance metrics for distribution of research protocols and
results, development of standards for data sharing practices and
introducing legally enforced policies on information sharing [6].
Ensure that research reports address the needs of research users
by encouraging better and more complete reporting and invest-
ing in the development and maintenance of an infrastructure for
reporting, reviewing and archiving [7].
. Is anyone listening?
These are of course very laudable aims and all make perfect
ense, yet it is hard not to cast a weary eye over previous such
ropositions, generally published by the same cohort of authors in
imilarly prominent high impact factor journals. It really is striking
ust for how long there have been reports about the poor quality
f research methodology, inadequate implementation of research
ethods and use of inappropriate analysis procedures as well as
ack of transparency of reporting. All have failed to stir researchers,
unders, regulators, institutions or companies into action.
For example, an earlier, shorter, but similar narrative of the
roblems facing applied research expressed surprise at the level
f waste caused by issues such as poorly designed research stud-
es pursuing the wrong questions, then either delaying or failing to
ublish in peer-reviewed journals and ﬁnally reporting outcomes
electively [9]. The authors’ list of recommendations to address
hese issues was rather similar to the ones published ﬁve years later,d Quantiﬁcation 2 (2014) 35–42
and is echoed by several complementary analyses of the challenges
facing – omics research with regards to sample size and bias [10],
validation practices [11] and design, conduct, and analysis of such
studies [12]. Whether these expositions have had much impact is
anyone’s guess, but the fact that there is an unremitting reiteration
of the same issues suggests not. Remarkably in this age of sup-
posed austerity, neither politicians nor the public seem to care that
the majority of research effort is wasted. It is shocking that whilst
primary health care budgets are being trimmed, patient waiting
times are increasing and the medical infrastructure is crumbling,
no media investigation scrutinises the huge waste that is so evident
to researchers themselves and, if stopped, would bring huge bene-
ﬁts to “our health, our comfort and our grasp of truth” [12]. It is truly
extraordinary that whilst most researchers are aware of the funda-
mental ﬂaws afﬂicting biomedical research, very few individuals,
institutions, journal editors or funding agencies are prepared to put
their heads above the parapet of what sometimes looks suspiciously
like conspiratorial silence.
4. Lack of reproducibility
There has been a view for some time that the major prob-
lem no longer is the validity of expression measurements, but
rather, the reliability of inferences from the data [13]. This conve-
niently disregards the fact that the results from thousands of these
studies remain in the scientiﬁc literature and are likely to con-
fuse current opinions and confound future studies. Furthermore,
whilst inappropriate data analysis is of course a major problem,
the widespread disregard for and dismissal of technical variability
continues to be at the heart of much of the reproducibility endemic
in biomedical research. This is most obviously demonstrated by
the fact that independent researchers cannot reproduce the vast
majority of peer-reviewed published work.
Whilst repeatability, the successful replication of results and
conclusions from one study in the same laboratory, is important,
reproducibility, deﬁned as the independent conﬁrmation of results
and conclusions from a study, is the bedrock on which the scien-
tiﬁc principle is based. Sadly, it has become clear that the results
reported by most publications in the biomedical ﬁeld do not ful-
ﬁl that basic criterion. In a recent investigation at least half of
researchers surveyed had the personal experience of being unable
to reproduce published data and many were unable to resolve the
issue even when helped by original authors [14]. In another inves-
tigation 11/12 (92%) studies could not be reproduced when the
methods outlined in the original papers were replicated exactly,
26/38 (68%) when the methods were adapted and 2/2 (100%)
when different methods were used [15]. Incidentally, it is unclear
whether the authors analysed 67 or 57 projects, as the numbers
from one of their ﬁgures add up to 67, whereas those from another
add up to 57. A third study could not reproduce 47/53 (89%) of
ﬁndings even when the laboratories that conducted the original
experiments were consulted about their methods and, in some
cases, experiment were repeated in the original laboratory [16].
Tellingly, all studies for which ﬁndings could be reproduced pro-
vided complete information on reagents and authors had paid close
attention to controls and investigator bias. An examination of 271
in vivo studies using rodent models or non-human primates con-
cluded that only 60% of the articles included information about the
number and characteristics of the animals and only 70% provided
detailed descriptions of the statistical analyses [17]. In a similar
vein, 54% of all resources referred to in over 200 recent publications
in the ﬁelds of Neuroscience, Developmental Biology, Immunology,
Cell and Molecular Biology and General Biology could not be ade-
quately identiﬁed, regardless of domain, journal impact factor, or
reporting requirements [18]. Yet another investigation set out to
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ssess the study design, statistical analyses, and reporting of 156
apers published in 2008 on cerebrovascular research. Few papers
ere hypothesis-driven or properly designed, many did not include
dequate information on methods and results and were charac-
erised by poor statistical details [19]. All these events lead to the
nevitable conclusion that there is a spectacular lack of attention to
etail by researchers, reviewers and editors.
. Technical issues
The viewpoint that there is no longer a problem with the valid-
ty of expression measurements is also challenged by the clear
vidence that molecular techniques can be unﬁt for purpose. The
roblems associated with real-time quantitative PCR (qPCR) have
een extensively aired [20–28], but the emphasis on qPCR has
oncealed the complications associated with the reverse transcrip-
ion (RT) step, which converts RNA into cDNA. RT is a basic and
ssential molecular technique that feeds into a number of other
ethods that have become the mainstay of applications in modern
iology, diagnostics, medicine, forensics and biotechnology. This
eaction is carried out by a choice of different enzymes with dif-
erent properties that are not just enzyme-speciﬁc but are also
ependent on the advanced buffers supplied with the enzymes.
here was early recognition that a consideration of mRNA struc-
ure is essential prior to any investigation into gene expression
29] and that reverse transcriptases (RTases) differ in their ability
o transcribe through the extensive secondary structure in mRNA
30,31]. This led to the realisation that both technical and biolog-
cal variability had to be considered when analysing results from
T-qPCR experiments and that the variability of the RT step pre-
ented an important impediment to reliable data interpretation
32]. Subsequent reports showed that the method of cDNA priming
ffects both accuracy and reproducibility of RT-qPCR experiments
33,34] and that reactions primed by target-speciﬁc primers are
inear over a wider range than similar reactions primed by random
rimers [35]. The ﬁrst empirical evidence for high variability being
n inherent property of the RT step was provided in 2004 with two
ather important, but woefully overlooked publications. The ﬁrst
howed that RT-qPCR gene expression measurements are compa-
able only when the same priming strategy, reaction conditions
nd RNA concentration are used in all experiments [36]. The sec-
nd reported RT- and target-dependent cDNA yields that differed
y up to 100-fold [37], something that also applies to digital RT-PCR
38]. The paper’s judicious recommendation that assays should be
un at least as duplicates starting with the reverse transcription
eaction continues to be ignored, even though the soundness of
hat advice was demonstrated by a follow-up publication [39]. Yet
nother paper reported gene-related factors as the primary deter-
inants of RT variability and called for an evaluation of the RT
obustness of control genes in RT-qPCR normalisation [40]. A recent
aper has demonstrated that the fold changes reported by most
NA biomarkers are well within the range of variability observed
hen multiple RT reactions are carried out on the same template
41]. The conclusions from these papers are rather stark and place
uestion marks behind many of the results reported not just in
he biomedical literature but in the scientiﬁc literature as a whole.
nfortunately, recommendations for improvement are universally
gnored and a large number of publications that use the RT step
re characterised by inadequate and non-transparent reporting
nd conclusions that are based on expression changes well within
xperimental variability.. MIQE
The “minimum information for publication of qPCR experi-
ents” (MIQE) guidelines constitute a list of recommendations thatd Quantiﬁcation 2 (2014) 35–42 37
target the reliability of qPCR results, with the aim of helping to
ensure the integrity of the scientiﬁc literature, promote consistency
between laboratories, and increase experimental transparency
[25]. They are the most widely cited of such initiatives, which
include MIAME  [42] and MISFISHIE [43] targeted at various molec-
ular techniques. MIQE is based on an earlier proposal aimed
at improving the quality of RT-qPCR experiments in 2002 [44]
and covers every aspect important to the qPCR assay itself, as
well as issues relating to pre- and post-assay parameters. By
2009 it was pretty obvious that many publications using PCR-
based methods were seriously ﬂawed and that this impaired
the readers’ ability to evaluate critically the quality of the pub-
lished results. The actual trigger for the publication of the MIQE
guidelines was provided by the after effects of a paper that
used RT-qPCR to detect measles virus in children with autism
[45]. These results were never reproduced independently [46–48]
nor repeated by the authors themselves [49]. An analysis of the
raw data underlying the original publication revealed a series of
mistakes, inappropriate analysis methods and misinterpretations
that completely invalidated any of the paper’s ﬁndings [50,51].
Despite the presentation of detailed evidence at the major autism
trials in 2007 in the USA, three initial judgements and three
subsequent appeals judgements conﬁrming that the underlying
data were unreliable, this paper has never been retracted and
its false conclusions remains unrestricted in the scientiﬁc litera-
ture.
The number of citations of the original MIQE publication in
the peer-reviewed literature has just passed 3000, it has been fol-
lowed by several editorials on their implementation [26,52,53]
and has encouraged the publication of the MIQE guidelines for
digital PCR [54]. All major instrument and reagent manufactur-
ers incorporate the guidelines into training their ﬁeld application
specialists, actively encourage their implementation, support and
organise world-wide workshops and publish effective guides to
help their realisation [55,56]. Unfortunately, researchers them-
selves are far less enthusiastic and in addition to the thousands
of peer-reviewed papers that are already published, thousands
more are published every year without regard for the MIQE guide-
lines and report results and conclusions that are unlikely to be
correct [57,58]. Recent surveys of qPCR-based publications found
that the problems addressed by the MIQE guidelines continue
to persist [28,59] and an investigation focusing on normalisation
procedures in RT-qPCR-associated colorectal cancer biomarkers
concluded that virtually none of the studies could be reliably
assessed [60].
7. Biomarkers
The identiﬁcation of clinically useful biomarkers has been one of
the most active areas of research, with tens of thousands of papers
claiming to have identiﬁed a wide range of diagnostic, prognostic or
predictive biomarkers of human disease [8]. However, conclusions
are often based on large-scale measurements of biological pro-
cesses that “drown” any understanding in a “sea of measurements”
[61] and inapplicable statistics [62]. This headlong stampede has
only occasionally been punctuated by thoughtful, insightful and
hence ignored counsels for cautions such as that provided by one
of the earliest discussions of biomarkers that also included a check-
list for evaluating their reliability prior to use in a clinical context
[63].
The starting point for most biomarkers continues to be the
analysis of microarray results, even though there is plenty of evi-
dence that should council caution. One study that deserves to
be considered more widely highlights the discordance between
microarray results and those from non-microarray-based clinical
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tions, with one analysis showing none [90] and another reporting
a strong correlation [91]. Certainly our own data show very clearly8 S.A. Bustin / Biomolecular Detect
nd biological data [64]. Others have identiﬁed poor study design
nd patient selection, reliance on p-value as well as technical and
nalytical issues as obstacles in the identiﬁcation of practically use-
ul biomarkers, and include recommendations for marker reporting
65,66]. A fairly recent report comments that “the most spectac-
lar published signatures predictive for chemotherapy response
re based on unreliable data” [67]. Another analysis is more opti-
istic in that it suggests that “reproducible [microarray] data can
e achieved and clinical standards are beginning to emerge”, but
dds the caveat that there is a need for establishing a suitable work-
ow to “correctly sample a tumour, isolate RNA and process this for
icroarray analysis, evaluate the data, and communicate ﬁndings
n a consistent and timely fashion” [68].
The need for easy and complete public data access [7] and
ata checklists [69] is highlighted by the results of studies that
eanalyse such data and cannot reproduce the original analyses.
n analysis of 46 microarray studies addressing major cancer out-
omes revealed that they were characterised by selective data
nalysis and discussion of results [70], whereas the analyses from
nly two of 18 microarray-based gene expression proﬁling stud-
es could be reproduced [71]. Suboptimal design and inadequate
ssay information are typical features of cancer prognostic marker
tudies [72] and when combined with the strong reporting bias
haracteristic of many articles suggests that this literature may
e largely unreliable [73]. The problem is as serious today as it
as ﬁve, ten and 15 years ago. A recent microarray study found
hat the human genomic response to acute inﬂammatory stresses
s not reproduced in current mouse models [74], a ﬁnding that
hallenges the use of mice as essential animal models in biomed-
cal research. However, a reanalysis of the data not only found
hat human and murine gene expression patterns associated with
nﬂammatory conditions are congruent, but also identiﬁed a num-
er of pathways commonly regulated in humans and mice [75].
ncidentally, analysis-related discordance is just as apparent in
ther biomedical areas of research: 35% of published reanaly-
es of data from randomised clinical trials (RCTs) led to changes
n ﬁndings that implied conclusions different from those of the
riginal article about the types and number of patients who
hould be treated [76]. In addition, not only are many publica-
ions describing RCT outcomes inconsistent with their protocol,
ut also there is clear evidence for publication as well as out-
ome reporting bias. Studies reporting signiﬁcant results are more
ikely to be published and outcomes that are statistically signif-
cant have higher odds of being fully reported [77]. If outcomes
f RCTs are to be clinically useful, there is an obvious need
o publish all results and outcomes, regardless of their signiﬁ-
ance.
Next generation sequencing (NGS), which allows hypothesis-
eutral analysis with accuracy and a wide dynamic range and
as started to supersede microarrays, is not exempt from these
hallenges. The variable lengths of RNA obtained after fragmen-
ation prior to sequencing can be a source of bias, resulting in
ncorrect ranking of differentially expressed genes [78] and the
echnical variability of transcriptome sequencing experiments is
ufﬁciently high so that RNA abundance estimates can substan-
ially disagree even when coverage levels are high [79]. Quality
ssessment of sequencing data also appears to be somewhat less
han complete, as witnessed by the surprise expressed by one group
f authors when they noticed that standard DNA alignment algo-
ithms assume that sequences are accurate and do not allow for
he systematic incorporation of quality parameters into sequence
lignments [80]. Unless prompt action is taken, it is easy to see
ow NGS data will become as unreliable as those obtained from
PCR and microarray experiments, except that there will be vastly
ore of them and troubleshooting will be proportionately more
ifﬁcult.d Quantiﬁcation 2 (2014) 35–42
8. Hype and retractions
The peer-reviewed literature is widely perceived as comprising
articles that have been carefully evaluated by experts in the ﬁeld for
methodological consistency, completeness and soundness as well
as for the logical consistency of scientiﬁc claims based on experi-
mental results. Whilst it is acknowledged that not every conclusion
is correct and that subsequent new data can lead to a re-evaluation
of those ﬁndings, the combination of rigorous peer-review and pub-
lication in reputable journals bestows on peer-reviewed papers the
appearance of abidance, authenticity and authority.
Whatever the veracity of this perception, the route by which
research ﬁndings are disseminated to a wider public is consider-
ably less assured. An examination of press releases by high-proﬁle
medical journals found that these do not routinely highlight study
limitations, disclose the role of industry funding and present ﬁnd-
ings perceived to be newsworthy in a way that may  exaggerate
their importance [81]. The somewhat unhelpful advice of Nature
Genetics for a scientist who  ﬁnds his work being thus gloriﬁed
is to reduce the hype by explaining the implications of the work
clearly “without using our ﬁeld’s rich jargon” [82]. Unselective
press coverage is also apparent, as demonstrated by a study that
followed up the work presented in 147 conference abstracts and
reported in 252 news stories [83]. After three years 25% of abstracts
remained unpublished, 25% were published in low impact factor
journals and 50% in journals with high impact factors. Thirty-nine
publications chosen for front-page coverage followed the same
pattern, suggesting that media attention is undiscerning and not
focused on quality research. Most of these reports would have
been preliminary ﬁndings with tentative validity and indiscrimi-
nate press coverage is likely to create a misplaced impression of
conﬁdence and validity and is detrimental to engendering trust in
research or individuals engaged in research. Interestingly, some-
times even researchers themselves cannot agree on the relevance
of their own  published work. It should not be unreasonable to
expect that all authors contributing to a research publication
agree on the interpretation of results and any conclusions that
are put forward. Remarkably, that is not necessarily the case
as revealed by the results of a small study of ten papers that
appeared in The Lancet [84]. These indicated that the discus-
sions did not reﬂect the opinions of all contributing authors and
that the authors frequently disagreed about the importance and
implications of their own ﬁndings and where their research was
heading.
Sometimes, it is necessary for a published article to be retracted.
For example, a high proﬁle article that used publicly available data
to identify signatures from microarray proﬁles of human cancer cell
lines with known in vitro drug sensitivity or resistance to predict
in vivo chemotherapeutic responses [85] had to be withdrawn [86]
after clinical trials had started because independent reanalysis of
the data showed unintentional mislabelling and indexing errors
that resulted in none of the original results being reproducible
[87]. Retractions make up a miniscule percentage of all publica-
tions (871/>17 million between 1950 and 2007) [88], although the
number of articles retracted per year has increased by between 11-
and 19-fold from 2001 to 2010 [89]. Editors of high impact fac-
tor journals often use another device, “expressions of concern”,
prior to retraction to question published data, with six journals
accounting for 40% of such notiﬁcations [89]. Ironically, there is
disagreement in the literature about the effects and subsequent
impacts of retracted publications. It is not clear whether there is
a correlation between journal impact factor and number of retrac-that there is a negative correlation between transparency of repor-
ting and journal impact factor [28].
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Table  1
A search was  carried out on the Nature web site (www.nature.com) for the term “reverse transcription real time PCR” and ten papers published in the second half of 2014
were  selected at random. Materials and methods and supplementary information was  examined for information on RT-qPCR protocols.
Reference [130] [131] [132] [133] [134] [135] [136] [137] [138] [139]
RNA integrity No No No No No No No No No No
RNA  purity No No No No No No No No No No
RT  conditions No No No No No No No No No No
PCR  efﬁciency No No No No No No No No No No
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Reference genes -Actin 18S rRNA 18S rRNA GAPDH
Validated No No No No 
The most common reason for retraction is the uncovering of a
cientiﬁc mistake, although there is increasing evidence of fabri-
ation and data plagiarism [92–94]. Neither cause is usually cited
s a reason for retraction [95], even though these papers represent
 calculated effort to deceive [96]. Hence it is rather disconcerting
hat retractions may  not be an effective means of removing fraud-
lent results from the literature [97]. An analysis of the impact of
etracted articles in the biomedical literature from 1966 to 1997
ound that even after publication of the retraction most of these
rticles continue to be cited as valid work with no mention of the
etraction [92], with most citations implicitly or explicitly positive
98] even up to 24 years post retraction [99]. A more recent publica-
ion also found that a retraction did not affect the paper’s citations
ate within 12 months of retraction [100] and an investigation of the
ffect of rebuttals on seven high-proﬁle original articles found that
riginal articles were cited much more frequently than the rebut-
als, with no reduced effect on annual citation numbers [101]. In
ontrast, other reports found that retraction signiﬁcantly reduced
ubsequent citation [102,103] and that this reduction extends to
he authors’ other published work [104]. Remarkably, an unex-
ected 18% of authors self-cite retracted work post retraction [why
ould they do that?], but only 10% of those authors also cite the
etraction notice [105]. Around 1% of the NIH budget between 1992
nd 2012 (US$58 million) was spent on papers retracted due to
isconduct, with each article accounting for a mean of $392,582 in
irect costs [106]. Not surprisingly, there have been calls to institute
ore aggressive means of notiﬁcation to the scientiﬁc community
107], yet the topic is rarely mentioned and different publishers dif-
er in their retraction policies, which can make it not immediately
bvious that a paper has been retracted [108]. Although retrieval
f a publication in PubMed also retrieves the retraction statement,
uthors often rely on other authors’ citation to that work and so
nadvertently enhance that articles legitimacy.
. Biological relevance
I would like to conclude with a brief mention of another rea-
on for the low ratio of translation of research promise to real-life
iomedical application. Much biomedical research is performed in a
linical and methodological vacuum [109] and research ﬁndings are
requently extrapolated from disease models that have little resem-
lance to the corresponding human condition [110]. Even though
heir unsuitability is occasionally recognised [111–118], there is a
eed to acknowledge more universally and transparently the limi-
ations in the clinical translation of non-human models in general
o man  [119]. No matter how transparent, well-designed, analysed
nd reported, if research results are obtained from inappropriate
odels they can never be translated into a valid human disease
ontext.0. Conclusions
Late in the day, editors of some of the major scientiﬁc journals
ave come to realise that they have been seriously negligent in theirYes Yes Yes Yes Yes Yes
Rpl32 GAPDH Actin HPRT GAPDH GAPDH
No No No No No No
approach to overseeing the publication of reliable research results
and have started to confront their responsibilities [120–122]. A
series of similarly worded editorials appeared in Nature Structural
Biology [123], Nature Genetics [124], Nature Neuroscience [125],
Nature Immunology [126], Nature Medicine [127], Nature Meth-
ods [128], Nature Cell Biology [129] and announced measures to
“reduce irreproducibility”. These are a welcome, if long overdue
acknowledgement of the journals’ acquiescence to such vast quan-
tities of inadequate reporting of experimental detail in much of the
peer-reviewed literature.
However, the proof is in the pudding and an analysis of ten
random papers published in late 2014 in Nature-titled journals
[130–139] reveals the astonishing fact that there is actually less
technical information provided than in the past (Table 1). Every
single publication uses a single, unvalidated reference gene for nor-
malisation (all old favourites), all use the 2−Cq method with no
attempt to calculate PCR efﬁciency and reporting of RNA quality
control measures is non-existent. Yet for the Cq calculation
to be valid, the ampliﬁcation efﬁciencies of target and reference
must be approximately equal [140]; if not the PCR must be opti-
mised [141]. What hope of ever changing anything if journal editors
choose to ignore their own guidelines?
In contrast, research published in Biomolecular Detection and
Quantiﬁcation (BDQ) will have to pass a careful double blind peer-
review process that will examine the validity of its molecular
study design, measurement, data analysis and reporting. Our aim
is to establish a reputation for unbiased publishing of studies
that adhere to best practice guidelines and promote excellence
in molecular measurement and its data analysis. Subject areas are
deliberately broad to allow BDQ to serve as a repository for sharing
key ﬁndings across what may  otherwise be disparate specialties.
It is hoped that BDQ will attract a wide range of critical, thought-
ful, well-designed and excellent publications to help provide the
impetus towards a more transparent and meaningful scientiﬁc lit-
erature.
Finally, the question “Modern biomedical research: an internally
self-consistent universe with little contact with medical reality?”
[110] should now be extended to include the addition “and based on
an unacceptable level of technical proﬁciency”. It will be a long time
before the many contradictions apparent in every area of the life sci-
ences are addressed, never mind corrected [142]. But who  is going
to lead this effort, and how many vested interests will conspire to
retain the status quo?
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